Edgewise Therapeutics (EWTX) Free Cash Flow (2020 - 2026)

Edgewise Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$42.6 million in Q1 2026.

• Quarterly Free Cash Flow fell 12.33% year-over-year to -$42.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$148.7 million (down 25.75% YoY) and the FY2025 annual result came in at -$144.0 million, down 32.04% from the prior year.
• Free Cash Flow fell to -$42.6 million in Q1 2026 per EWTX's latest filing, from -$38.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$12.1 million in Q4 2022 and troughed at -$42.6 million in Q1 2026.
• A 5-year average of -$26.4 million and a median of -$27.0 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 122.85% in 2023, then increased 3.81% in 2024.
• Over 5 years, Free Cash Flow stood at -$12.1 million in 2022, then sank by 122.85% to -$27.0 million in 2023, then gained by 3.81% to -$26.0 million in 2024, then slumped by 49.23% to -$38.7 million in 2025, then declined by 9.91% to -$42.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$42.6 million, -$38.7 million, and -$34.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.